| Literature DB >> 27834920 |
Rocio de la Iglesia1, Viviana Loria-Kohen2, Maria Angeles Zulet3,4, Jose Alfredo Martinez5,6, Guillermo Reglero7, Ana Ramirez de Molina8.
Abstract
Metabolic syndrome (MetS) is established as the combination of central obesity and different metabolic disturbances, such as insulin resistance, hypertension and dyslipidemia. This cluster of factors affects approximately 10%-50% of adults worldwide and the prevalence has been increasing in epidemic proportions over the last years. Thus, dietary strategies to treat this heterogenic disease are under continuous study. In this sense, diets based on negative-energy-balance, the Mediterranean dietary pattern, n-3 fatty acids, total antioxidant capacity and meal frequency have been suggested as effective approaches to treat MetS. Furthermore, the type and percentage of carbohydrates, the glycemic index or glycemic load, and dietary fiber content are some of the most relevant aspects related to insulin resistance and impaired glucose tolerance, which are important co-morbidities of MetS. Finally, new studies focused on the molecular action of specific nutritional bioactive compounds with positive effects on the MetS are currently an objective of scientific research worldwide. The present review summarizes some of the most relevant dietary approaches and bioactive compounds employed in the treatment of the MetS to date.Entities:
Keywords: bioactive compounds; dietary strategies; metabolic syndrome
Mesh:
Substances:
Year: 2016 PMID: 27834920 PMCID: PMC5133877 DOI: 10.3390/ijms17111877
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Criteria to define metabolic syndrome (MetS) depending on different organisms.
| World Health Organization (1994) [ |
|---|
| - Insulin resistance defined as the top 25% of the fasting insulin values among nondiabetic individuals. |
| - Central obesity: waist circumference ≥ 94 cm (Europids men), ≥ 80 (Europids women). |
BMI, body mass index; DBP, diastolic blood pressure; HDL-c, high density lipoprotein-cholesterol; SBP, systolic blood pressure; TG, triglycerides.
Potential beneficial effects of different dietary patterns on the treatment of MetS comorbidities.
| Dietary Pattern | Metabolic Diseases Improved | Mechanisms Implicated | Ref. |
|---|---|---|---|
| Energy-Restricted Diets | Obesity | Lipolysis | [ |
| Type 2 diabetes | Improvements of glycaemia and insulin resistance | ||
| Inflammation | ↓ Inflammatory markers (e.g., IL-6) | ||
| CV diseases | Improvement of cholesterol profile and ↓ SBP, DBP and TG | ||
| Diets Rich in Omega-3 | Inflammation | ↓ Pro-inflammatory cytokines (e.g., IL-6, TNFα) | [ |
| CV diseases | ↓ TG, sdLDL particles | ||
| Low Glycemic Index Diets | Type 2 diabetes | ↓ HbA1c and fructosamine | [ |
| High TAC Diets | Oxidative stress | Free radicals’ scavenger | [ |
| Moderate-High Protein Diets | Obesity | ↑ Satiety and thermogenesis | [ |
| High Meal Frequency | Obesity | ↓ Plasma glucose levels oscillations and ↓ insulin secretion | [ |
| The Mediterranean Diet | Type 2 diabetes | Glycemic control, ↓ HbA1c, ↓ fasting glucose levels | [ |
| CV diseases | ↓ TC, LDL-c, TG, and ↑ HDL-c | [ | |
| Obesity | ↑ satiety and ↓ body weight and waist circumference | [ |
BP, blood pressure; CV, cardiovascular; DBP, systolic blood pressure; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; IL-6, interleukin-6; LDL-c, low density lipoprotein cholesterol; SBP, diastolic blood pressure; sdLDL particles, small dense low density lipoprotein particles; TAC, total antioxidant capacity; TC, total cholesterol; TG, triglycerides; TNFα, tumor necrosis factor-alpha; ↓, reduction; ↑, increment.
Dietary bioactive compounds with potential positive effects on MetS, biological effects and molecular mechanisms of action involved.
| Bioactive Component | Metabolite Class | Biological Effects | Mechanisms | Ref. |
|---|---|---|---|---|
| Anthocyanins | Polyphenol | Antidiabetic | ↑ Glucose uptake in an insulin-independent mechanism | [ |
| Cardioprotective | ↑ BAFMD, HDL-c and ↓ VCAM-1, LDL-c | [ | ||
| Antiinflamatory | ↓ IL-8, IL-1β or CRP | [ | ||
| Ascorbate | Vitamin | Antioxidant | Scavenger of free radicals and regeneration of oxidized molecules | [ |
| Anti-inflammatory | ↓ CRP | |||
| Cardioprotective | ↑ eNOS and ↓ HDL-c glycation | |||
| Antidiabetic | ↑ SVCTs | |||
| Catechin | Polyphenol | Anti-obesity | ↑ ACAD and peroxisomal β-oxidation enzymes, ↓ COMT and PDE | [ |
| Cardioprotective | ↑ HDL-c and ↓ LDL-c, TC | |||
| Antidiabetic | ↓ Fasting glucose levels and insulin sensitivity improvement | |||
| Hydroxytyrosol | Polyphenol | Antioxidant | Free radical scavenger, radical chain breaker, and metal chelator | [ |
| Anti-inflammatory | ↑ eNOS, ↓ COX | |||
| Cardioprotective | ↑ HDL-c, ↓ LDL-c oxidation, ICAM-1, VCAM-1, LDL-c and TC | |||
| Quercetin | Polyphenol | Antioxidant | ↓ lipid peroxidation, ↑ antioxidant enzymes (e.g., SOD, CAT, GPX) | [ |
| Anti-inflammatory | ↓ PI3K, GLUT2, NFκB, TNF-α, MAPK, IL-6, IL-1β, IL-8 or MCP-1 | |||
| Anti-obesity | ↓ Adipogenesis through ↑ AMPK and ↓ C/EBPα, PPARγ, and SREBP-1 | |||
| Antidiabetic | PPARγ, GLUT2, PI3K and TK | |||
| ↓ Blood pressure | ↑ eNOS and ↓ platelet aggregation | |||
| Resveratrol | Polyphenol | Antioxidant | Scavenger of hydroxyl, superoxide, and metal-induced radicals | [ |
| Anti-inflammatory | ↓ NFκB, IL6, IL8, TNF-α, MCP-1, eNOS, COX | |||
| Cardioprotective | ↑ NO and Nrf2, ↓ ICAM-1, VCAM-1 | |||
| Anti-obesity | ↑ Lipolysis, ↓ lipogenesis | |||
| Anti-inflammatory | ↓ CRP, COX, PKC, IL-8, PAI-1 | |||
| Antiatherogenic | ↓ oxidation of LDL-c and PUFAs | |||
| Tocopherol | Vitamin | Antioxidant | ↓ lipid peroxyl radicals | [ |
| Anti-inflammatory | ↓ CRP, COX, PKC, IL-8 |
ACAD, acyl-CoA dehydrogenase; AFMD, artery flow-mediated dilation; AMPK, AMP-activated protein kinase; BAFMD, brachial artery flow-mediated dilation; CAT, catalase; C/EBPα, CCAAT-enhancer-binding protein-α; COMT, catechol-O-methyltransferase; COX, cyclooxygenase; CRP, C reactive protein; eNOS; endothelial nitric oxide synthase; GLUT2, glucose transporter 2; GPX, glutathione peroxidase; HDL-c, high density lipoprotein-cholesterol; ICAM-1, intercellular adhesion molecule; IL, interleukin; LDL-c, low density lipoprotein-cholesterol; MAPK, mitogen-activated protein kinases; MCP-1, monocyte chemoattractant protein-1; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NO; nitric oxide; Nrf2, NF-E2-related factor 2; PAI-1, activator inhibitor-1; PDE, phosphodiesterase; PI3K, phosphatidylinositol-3-kinase; PKC, protein kinase C; PPARγ, peroxisome proliferator-activated receptor gamma; PUFAs, polyunsaturated fatty acids; SOD, superoxide dismutase; SREBP-1; sterol regulatory element-binding protein 1; SVCTs, sodium-dependent vitamin C transporters; TC, total cholesterol; TK, tyrosine kinase; TNF-α, tumor necrosis factor α; VCAM-1, vascular cell adhesion protein 1; ↓, reduction; ↑, increment.
Figure 1Diagram of Metabolic syndrome comorbidities and dietary strategies and bioactive compounds described.